Last reviewed · How we verify
MRNA-1273.222 Vaccine
At a glance
| Generic name | MRNA-1273.222 Vaccine |
|---|---|
| Also known as | Spikevax Bivalent |
| Sponsor | Sheba Medical Center |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern (PHASE2, PHASE3)
- A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 (PHASE2, PHASE3)
- A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (PHASE3)
- Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines (PHASE1, PHASE2)
- A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants (PHASE2, PHASE3)
- An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)
- Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MRNA-1273.222 Vaccine CI brief — competitive landscape report
- MRNA-1273.222 Vaccine updates RSS · CI watch RSS
- Sheba Medical Center portfolio CI